European Medicines Agency warning on risk of arterial thrombosis with ponatinib

As a result of the meeting of the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP), 21-24 October 2013, the CHMP has declared that a review of product information is underway for ponatinib (Iclusig). Following the emergence of new data on the risk of arterial thrombosis with ponatinib, the CHMP concluded that the product information for prescribers and patients should be reviewed and amended if appropriate to include information and warnings about this risk. A formal procedure is currently underway to implement this update. Connect to the ESMO news release here.